1460880688-ed7117e4-814d-4942-90fb-a50fdf89727a

1. A semiconductor device, comprising:
a substrate;
an active fin protruding from the substrate and extending in a direction;
a gate structure crossing a first region of the active fin; and
a sourcedrain disposed on a second region of the active fin,
wherein the sourcedrain comprises upper surfaces and vertical side surfaces, wherein the vertical side surfaces are in substantially parallel with side surfaces of the active fin,
wherein an upper surface of the first region of the active fin is coplanar with an upper surface of the second region of the active fin,
wherein the sourcedrain is formed by crystal growth from the side surfaces and the upper surface of the active fin,
wherein the substrate is a {100}<110> substrate, the side surface of the active fin is a {110} surface, and the upper surface of the active fin is a {100} surface, and
wherein the side surfaces of the sourcedrain are {110} surfaces and the upper surfaces of the sourcedrain are {111} surfaces.
2.-5. (canceled)
6. The device of claim 1,
wherein the substrate is a {110}<110> substrate, the side surface of the active fin is a {100} surface, and the upper surface of the active fin is a {110} surface.
7. The device of claim 6,
wherein the side surfaces of the sourcedrain are {100} surfaces and the upper surfaces of the sourcedrain are {111} surfaces.
8.-10. (canceled)
11. A semiconductor device, comprising:
a substrate;
an active fin protruding from the substrate and extending in a direction;
a gate structure crossing a first region of the active fin; and
a sourcedrain disposed on a second region of the active fin,
wherein the sourcedrain comprises upper surfaces and vertical side surfaces, wherein the vertical side surfaces are in substantially parallel with side surfaces of the active fin,
wherein a first upper surface of the first region of the active fin is higher than a second upper surface of the second region of the active fin, and wherein a vertical side surface connects the first upper surface and the second upper surface,
wherein the sourcedrain is formed by crystal growth from the vertical side surface and the second upper surface of the active fin,
wherein the substrate is a {110}<110> substrate, the second upper surface is a {110} surface, and the vertical side surface is a {100} surface, and
wherein the side surfaces of the sourcedrain are {100} surfaces, and the upper surfaces of the sourcedrain are {111} surfaces.
12. The device of claim 1, further comprising an auxiliary contact layer covering the side and upper surfaces of the sourcedrain.
13. The device of claim 12,
wherein the auxiliary contact layer is a silicide layer including at least one of WSi2, MoSi2, TiSi2 and CoSi2.
14. The device of claim 12, further comprising a sourcedrain which is in contact with the auxiliary contact layer.
15. The device of claim 14,
wherein the auxiliary contact layer is interposed between the sourcedrain contact and the upper surfaces of the sourcedrain.
16. The device of claim 14,
wherein the auxiliary contact layer is interposed between the sourcedrain contact and the upper surfaces and the side surfaces of the sourcedrain.
17. The device of claim 14,
wherein the auxiliary contact layer is interposed between the sourcedrain contact and the upper surfaces and one side surface of the sourcedrain.
18. The device of claim 1,
wherein an end part of the active fin is a rounded shape.
19. The device of claim 1,
wherein the gate structure comprises a gate dielectric layer disposed along the side surfaces and an upper surface of the active fin, a gate electrode disposed along the gate dielectric layer, and a spacer disposed on side surfaces of the gate electrode.
20. A semiconductor device, comprising:
a substrate having an active fin, wherein the active fin includes a first region and a second region;
a gate electrode crossing the first region of the active fin and covering at least one side of the first region of the active fin;
a sourcedrain adjacent to the gate electrode and disposed on the second region of the active fin; and
a plug connected to the sourcedrain,
wherein the sourcedrain comprises upper surfaces, lower surfaces and vertical side surfaces, wherein the vertical side surfaces are in substantially parallel with side surfaces of the active fin, and
wherein each of the upper surfaces of the sourcedrain and each of the lower surfaces of the sourcedrain are connected to one end of a corresponding vertical side surface of the sourcedrain and the other end of the corresponding vertical side surface at an obtuse angle, respectively, so that each of the upper surfaces of the sourcedrain and each of the lower surface of the sourcedrain are sloped with respect to a corresponding vertical side surface of the sourcedrain.
21.-41. (canceled)

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of treating Alzheimer’s disease, the method comprising administering to a patient having Alzheimer’s disease a therapeutically effective amount of a compound of Formula I
36
wherein
Ra is hydrogen, C1-C6 alkyl, or
37
n is 0 to 5 inclusive;
R1, R2, R3, R4, R5, R6, and R7 are independently hydrogen, halogen, OH, NH2, NRbRc, CO2H, CO2C1-C6 alkyl, NO2, OC1-C12 alkyl, C1-C8 alkyl, CF3, CN, OCH2 phenyl, OCH2-substituted phenyl, (CH2)m-phenyl, O-phenyl, O-substituted phenyl,
CHCH-phenyl, O(CH2)pNRbRc,
38
NH(CH2)pNRbRc, N(C1-C6alkyl)(CH2)pNRbRc,
39
R8 is COOH, tetrazolyl, SO2Rd, or CONHSO2Rd;
Rb and RC are independently hydrogen, C1-C6 alkyl, (CH2)m-phenyl, or Rb and Rc taken together with the nitrogen atom to which they are attached form a cyclic ring selected from piperidinyl, pyrrolyl, imidazolyl, piperazinyl, 4-C1-C6 alkylpiperazinyl, morpholino, thiomorpholino, decahydroisoquinoline, or pyrazolyl;
Rd is hydrogen, C1-C6 alkyl, CF3, or phenyl;
m is 0 to 5 inclusive;
p is 1 to 5 inclusive;
A is CH or N;
R1 and R2, when adjacent to one another, can be methylene-dioxy;
or the pharmaceutically acceptable salts thereof.
2. The method of claim 1 wherein
Ra is hydrogen;
n is 2; and
R3 and R4 are hydrogen.
3. The method of claim 1 wherein
Ra is hydrogen;
R3 and R4 are hydrogen; and
n is 2 to 5 inclusive.
4. The method of claim 1 wherein
Ra is hydrogen;
n is 2;
R3 and R4 are hydrogen; and
R1, R2, and R7 are independently chlorine, N(CH2CH3)2, OH, CH3, fluorine, CF3, phenyl, hydrogen, OCH2 phenyl, O(CH2)3N(CH3)2, O phenyl, O(CH2)7CH3, CH(CH2OCH2CH3)2, pyrrolyl, CHCH-phenyl,
40
N(CH2)3CH32, substituted phenyl, OCH2 substituted phenyl, pyrrozolyl, or N(phenyl)2.
5. The method of claim 1 wherein
Ra is hydrogen;
n is 3, 4, or 5;
R3 and R4 are hydrogen; and
R1, R2, and R7 are independently chlorine or hydrogen.
6. The method of claim 1 wherein
Ra is hydrogen;
n is 2;
R3 and R4 are hydrogen; and
R5, R6, and R8 are independently hydrogen, CO2H, NO2, OCH3,
imidazolyl, CN, fluorine, CH3, CF3, halogen,
NHC1-C6 alkyl, N(C1-C6alkyl)2, NH2, or pyrrolyl.
7. The method of claim 1 wherein
Ra is hydrogen;
n is 2;
R3 and R4 are hydrogen; and
R5 is CO2H.
8. A method of treating Alzheimer’s disease, the method comprising administering to a patient having Alzheimer’s disease a therapeutically effective amount of a compound of Formula I
41
wherein
Ra is hydrogen;
n is 1 to 5 inclusive;
R3 and R4 are hydrogen;
R1, R7, and R2 are independently chlorine, N(CH2CH3)2, OH, CH3, fluorine, CF3, phenyl, hydrogen, OCH2 phenyl, O(CH2)3N(CH3)2, O phenyl, O(CH2)7CH3, CH(CH2OCH2CH3)2, pyrrolyl, CHCH-phenyl, N(CH2)3CH32, substituted phenyl, OCH2-substituted phenyl, pyrazolyl, or N(phenyl)2;
R5 and R6 are independently hydrogen, CO2H, NO2, OCH3, imidazolyl, CN, fluorine, CH3, CF3, or pyrrolyl;
R8 is COOH or tetrazolyl;
or the pharmaceutically acceptable salts thereof.
9. The method of claim 1 wherein the compound of Formula I is:
2-4-2-(3,4-Dichlorophenyl)ethylphenylamino-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethylphenylamino-5-nitrobenzoic acid;
2-4-4-(3,4-Dichloro-phenyl)-ethylphenylamino-4-methoxy-5-nitrobenzoic acid;
2-4-2-(3,4-Dihydroxy-phenyl)-ethyl-phenylaminobenzoic acid;
2-4-2-(4-Dibutylamino-phenyl)-ethylphenylaminobenzoic acid;
2-4-2-(3,4,5-Trihydroxy-phenyl)-ethylphenylaminobenzoic acid;
2-4-3-(3,4-Dichlorophenyl)propylphenylamino-4-methoxy-5-nitrobenzoic acid;
2-4-3-(3,4-Dichlorophenyl)propylphenylamino-4-imidazo-1-yl-5-nitrobenzoic acid;
2-4-3-(3,4-Dichlorophenyl)-propylphenylaminobenzoic acid;
2-4-4-(3,4-Dichlorophenyl)butylphenylaminobenzoic acid;
2-4-4-(3,4-Dichloro-phenyl)-butyl-phenylamino-5-nitro-benzoic acid;
2-4-4-(3,4-Dichlorophenyl)-butylphenylamino-3,5-dinitrobenzoic acid;
2-4-5-(3,4-Dichlorophenyl)pentylphenylamino-5-nitrobenzoic acid;
2-4-5-(3,4-Dichloro-phenyl)pentylphenylamino-4-methoxy-5-nitrobenzoic acid;
2-4-(3,4-Dichloro-benzyl)-phenylamino-benzoic acid;
2-4-2-(3,4-Dimethyl-phenyl)-ethyl-phenylamino-5-nitro-benzoic acid;
2-4-2-(3,4-Difluoro-phenyl)-ethyl-phenylamino-5-nitro-benzoic acid;
2-4-2-(4-Chloro-3-trifluoromethyl-phenyl)-ethyl-phenylamino-benzoic acid;
2-4-(2-Biphenyl-4-yl-ethyl)-phenylamino-5-nitro-benzoic acid;
5-Nitro-2-(4-phenethyl-phenylamino)-benzoic acid;
2-(4-Phenethyl-phenylamino)-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-5-methoxy-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-terephthalic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-5-methyl-benzoic acid;
4-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-isophthalic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-5-methanesulfonyl-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-5-imidazol-1-yl-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-6-nitro-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-4-nitro-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-3-nitro-benzoic acid;
5-Cyano-2-4-2-(3,4-dichloro-phenyl)-ethyl-phenylamino-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-4,6-difluoro-benzoic acid;
6-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-2,3-difluoro-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-6-fluoro-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-3-fluoro-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-3-methyl-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-4-fluoro-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-3,5-difluoro-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-3-trifluoromethyl-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-6-trifluoromethyl-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-5-trifluoromethyl-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-5-pyrrol-1-yl-benzoic acid;
2-4-2-(4-Benzyloxy-phenyl)-ethyl-phenylamino-benzoic acid;
2-(4-2-4-(3-Dimethylamino-propoxy)-phenyl-ethyl-phenylamino)-benzoic acid;
2-4-2-(4-Diethylamino-phenyl)-ethyl-phenylamino-benzoic acid;
2-4-2-(4-Phenoxy-phenyl)-ethyl-phenylamino-benzoic acid;
2-4-2-(4-Octyloxy-phenyl)-ethyl-phenylamino-benzoic acid;
2-(4-2-4-(2-Ethoxy-1-ethoxymethyl-ethyl)-phenyl-ethyl-phenylamino)-benzoic acid;
2-4-2-(4-Pyrrol-1-yl-phenyl)-ethyl-phenylamino-benzoic acid;
2-4-2-(4-Styryl-phenyl)-ethyl-phenylamino-benzoic acid;
2-4-2-(4-Dibutylamino-phenyl)-ethyl-phenylamino-benzoic acid;
2-4-2-(4-Ethyl-biphenyl-4-yl)-ethyl-phenylamino-benzoic acid;
2-4-2-(4-Octyl-phenyl)-ethyl-phenylamino-benzoic acid;
2-(4-2-3-(3,5-Dichloro-phenoxy)-phenyl-ethyl-phenylamino)-benzoic acid;
2-(4-2-4-(2-Chloro-6-fluoro-benzyloxy)-phenyl-ethyl-phenylamino)-benzoic acid;
2-4-2-(4-Pyrazol-1-yl-phenyl)-ethyl-phenylamino-benzoic acid;
2-4-2-(4-Diphenylamino-phenyl)-ethyl-phenylamino-benzoic acid;
2-(4-2-4-(3,4-Dichloro-benzyloxy)-phenyl-ethyl-phenylamino)-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-5-amino-benzoic acid;
2-4-2-(3,4-Dichloro-phenyl)-ethyl-phenylamino-5-trifluoromethyl-benzoic acid;
2-4-2-(3,4-Dichlorophenyl)phenylamino-5-nitrobenzoic acid;
2-4-3-(3,4-Dichlorophenyl)propylphenylamino-5-nitrobenzoic acid;
2-4-2-(3,4-Dimethyl-phenyl)-ethylphenylamino-5-nitrobenzoic acid;
2-4-2-(4-Chloro-3-trifluoromethylphenyl)ethylphenylamino-benzoic acid; or
2-4-(3,4-Dichlorophenyl)phenylaminobenzoic acid.
10. A method of inhibiting the aggregation of amyloid proteins to form amyloid deposits, the method comprising administering to a patient in need of inhibition of the aggregation of amyloid protein an amyloid protein aggregation inhibiting amount of a compound of Formula I
42
wherein
Ra is hydrogen, C1-C6 alkyl, or
43
n is 0 to 5 inclusive;
R1, R2, R3, R4, R5, R6, and R7 are independently hydrogen, halogen, OH, NH2, NRbRc, CO2H, CO2C1-C6 alkyl, NO2, OC1-C12 alkyl, C1-C8 alkyl, CF3, CN, OCH2 phenyl, OCH2-substituted phenyl, (CH2)m-phenyl, O-phenyl, O-substituted phenyl,
CHCH-phenyl, O(CH2)pNRbRc,
44
NH(CH2)pNRbRc, N(C1-C6alkyl)(CH2)pNRbRc,
45
R8 is COOH, tetrazolyl, SO2Rd, or CONHSO2Rd;
Rb and Rc are independently hydrogen, C1-C6 alkyl, (CH2)m-phenyl, or Rb and RC taken together with the nitrogen atom to which they are attached form a cyclic ring selected from piperidinyl, pyrrolyl, imidazolyl, piperazinyl, 4-C1-C6 alkylpiperazinyl, morpholino, thiomorpholino, decahydroisoquinoline, or pyrazolyl;
Rd is hydrogen, C1-C6 alkyl, CF3, or phenyl;
m is 0 to 5 inclusive;
p is 1 to 5 inclusive;
A is N;
R1 and R2, when adjacent to one another, can be methylene-dioxy;
or the pharmaceutically acceptable salts thereof.
11. The method of claim 10 wherein
Ra is hydrogen;
n is 2; and
R3 and R4 are hydrogen.
12. The method of claim 10 wherein
Ra is hydrogen;
R3 and R4 are hydrogen; and
n is 2 to 5 inclusive.
13. The method of claim 10 wherein
Ra is hydrogen;
n is 2;
R3 and R4 are hydrogen; and
R1, R2, and R7 are independently chlorine, N(CH2CH3)2, OH, CH3, fluorine, CF3, phenyl, hydrogen, OCH2 phenyl, O(CH2)3N(CH3)2, O phenyl, O(CH2)7CH3, CH(CH2OCH2CH3)2, pyrrolyl, CHCH-phenyl,
46
N(CH2)3CH32, substituted phenyl, OCH2-substituted phenyl, pyrazolyl, or
N(phenyl)2.
14. The method of claim 10 wherein
Ra is hydrogen;
n is 3, 4, or 5;
R3 and R4 are hydrogen; and
R1, R2, and R7 are independently chlorine or hydrogen.
15. The method of claim 10 wherein
Ra is hydrogen;
n is 2;
R3 and R4 are hydrogen; and
R5 and R6 are independently hydrogen, CO2H, NO2, OCH3, imidazolyl, CN, fluorine, CH3, CF3, halogen,
NHC1-C6 alkyl, N(C1-C6alkyl)2, NH2, or pyrrolyl.
16. The method of claim 10 wherein
Ra is hydrogen;
n is 2;
R3 and R4 are hydrogen; and
R8 is CO2H.
17. A method of inhibiting the aggregation of amyloid proteins to form amyloid deposits, the method comprising administering to a patient in need of inhibition of the aggregation of amyloid protein an amyloid protein aggregation inhibiting amount of a compound of Formula I
47
wherein
Ra is hydrogen;
n is 1 to 5 inclusive;
R3 and R4 are hydrogen;
R1, R7, and R2 are independently chlorine, N(CH2CH3)2, OH, CH3, fluorine, CF3, phenyl, hydrogen, OCH2 phenyl, O(CH2)3N(CH3)2, O phenyl, O(CH2)7CH3, CH(CH2OCH2CH3)2, pyrrolyl, CHCH-phenyl, N(CH2)3CH32, substituted phenyl, OCH2-substituted phenyl, pyrazolyl, or N(phenyl)2;
R5 and R6 are independently hydrogen, CO2H, NO2, OCH3, imidazolyl, CN, fluorine, CH3, CF3, or pyrrolyl;
R8 is COOH or tetrazolyl;
A is N;
R1 and R2, when adjacent to one another, can be methylene-dioxy;
or the pharmaceutically acceptable salts thereof.
18-21. (Cancelled).
22. The compounds:
4-4-2-(3,4-Dicloro-phenyl)-ethyl-phenylamino-nicotinic acid.
23-27. (Cancelled).
28. A method of imaging amyloid deposits, the method comprising:
a. introducing into a patient a detectable quantity of a labeled compound having the Formula I or a pharmaceutically acceptable salt thereof:
48
wherein
Ra is hydrogen, C1-C6 alkyl, or
49
n is 0 to 5 inclusive;
R1, R2, R3, R4, R5, R6, and R7 are independently hydrogen, halogen, OH, NH2, NRbRc, CO2H, CO2C1-C6 alkyl, NO2, OC1-C12 alkyl, C1-C8 alkyl, CF3, CN, OCH2 phenyl, OCH2-substituted phenyl, (CH2)m-phenyl, O-phenyl, O-substituted phenyl,
CHCH-phenyl, O(CH2)pNRbRc,
50
NH(CH2)pNRbRc, N(C1-C6alkyl)(CH2)pNRbRc,
51
R8 is COOH, tetrazolyl, SO2Rd, or CONHSO2Rd;
Rb and Rc are independently hydrogen, C1-C6 alkyl, (CH2)m-phenyl, or Rb and Rc taken together with the nitrogen atom to which they are attached form a cyclic ring selected from piperidinyl, pyrrolyl, imidazolyl, piperazinyl, 4-C1-C6 alkylpiperazinyl, morpholino, thiomorpholino, decahydroisoquinoline, or pyrazolyl;
Rd is hydrogen, C1-C6 alkyl, CF3, or phenyl;
m is 0 to 5 inclusive;
p is 1 to 5 inclusive;
A is CH or N;
R1 and R2, when adjacent to one another, can be methylene-dioxy;

or the pharmaceutically acceptable salts thereof.
b. allowing sufficient time for the labeled compound to become associated with amyloid deposits; and
c. detecting the labeled compound associated with the amyloid deposits.
29. The method of claim 28 wherein the patient has or is suspected to have Alzheimer’s disease.
30. The method of claim 28 wherein the labeled compound is a radio labeled compound.
31. The method of claim 28 wherein the labeled compound is detected using MRI.
32-41. (Cancelled).
42. A compound of Formula I.
52
wherein
Ra is hydrogen, C1-C6 alkyl, or
53
n is 0 to 5 inclusive;
R1, R2, R3, R4, R5, R6, and R7 are independently hydrogen, halogen, OH, NH2, NRbRc, CO2H, CO2C1-C6 alkyl, NO2, OC1-C12 alkyl, C1-C8 alkyl, CF3, CN, OCH2 phenyl, OCH2-substituted phenyl, (CH2)m-phenyl, O-phenyl, O-substituted phenyl,
CHCH-phenyl, O(CH2)pNRbRc,
54
NH(CH2)pNRbRc, N(C1-C6alkyl)(CH2)pNRbRc,
55
R8 is COOH, tetrazolyl, SO2Rd, or CONHSO2Rd;
Rb and Rc are independently hydrogen, C1-C6 alkyl, (CH2)m-phenyl; or Rb and Rc taken together with the nitrogen atom to which they are attached form a cyclic ring selected from piperidinyl, pyrrolyl, imidazolyl, piperazinyl, 4-C1-C6 alkylpiperazinyl, morpholino, thiomorpholino, decahydroisoquinoline, or pyrazolyl;
Rd is hydrogen, C1-C6 alkyl, CF3, or phenyl;
m is 0 to 5 inclusive;
p is 1 to 5 inclusive;
A is CH or N;
R1 and R2, when adjacent to one another, can be methylene-dioxy;
or the pharmaceutically acceptable salts thereof.
43. A pharmaceutical formulation comprising a compound of claim 42 admixed with a pharmaceutically acceptable diluent, excipient, or carrier therefor.